{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T14:20:12Z","timestamp":1761402012666},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec><jats:title \/><jats:p>Background: The cannabinoid system may be involved in the humoral mechanisms at the neuromuscular junction. Ultramicronized-palmitoylethanolamide (\u03bcm-PEA) has recently been shown to reduce the desensitization of Acetylcholine (ACh)-evoked currents in denervated patients modifying the stability of ACh receptor (AChR) function. &lt;p&gt; Objective: To analyze the possible beneficial effects of \u03bcm-PEA in patients with myasthenia gravis (MG) on muscular fatigue and neurophysiological changes. &lt;p&gt; Method: The duration of this open pilot study, which included an intra-individual control, was three weeks. Each patient was assigned to a 1-week treatment period with \u03bcm-PEA 600 mg twice a day. A neurophysiological examination based on repetitive nerve stimulation (RNS) of the masseteric and the axillary nerves was performed, and the quantitative MG (QMG) score was calculated in 22 MG patients every week in a three-week follow-up period. AChR antibody titer was investigated to analyze a possible immunomodulatory effect of PEA in MG patients. &lt;p&gt; Results: PEA had a significant effect on the QMG score (p=0.03418) and on RNS of the masseteric nerve (p=0.01763), thus indicating that PEA reduces the level of disability and decremental muscle response. Antibody titers did not change significantly after treatment. &lt;p&gt; Conclusion: According to our observations, \u03bcm-PEA as an add-on therapy could improve muscular response to fatigue in MG. The possible modulation of AChR currents as a means of eliciting a direct effect from PEA on the conformation of ACh receptors should be investigated. The co-role of cytokines also warrants an analysis. Given the rapidity and reversibility of the response, we suppose that PEA acts directly on AChR, though further studies are needed to confirm this hypothesis.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871527318666190131121827","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:16:09Z","timestamp":1549019769000},"page":"232-238","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment"],"prefix":"10.2174","volume":"18","author":[{"given":"Emanuela","family":"Onesti","sequence":"first","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Frasca","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ceccanti","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Gori","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Cambieri","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Libonati","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Palma","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Institute Pasteur- Fondazione Cenci Bolognetti, University of Rome Sapienza, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Inghilleri","sequence":"additional","affiliation":[{"name":"Rare Neuromuscular Diseases Centre, Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"Gilhus N.E.","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Lancet, Myasthenia gravis: subgroup classification and therapeutic strategies., 2015, 14, 1023-1036,","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"Sanders D.B.","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M. Neurology, International consensus guidance for management of myasthenia gravis: executive summary., 2016, 87, 419-425,","journal-title":"Neurology"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0028-3908(88)90083-4","volume":"27","author":"Turkanis S.A.","year":"1988","unstructured":"Turkanis SA, Karler R. Neuropharmacology, Changes in neurotransmitter release at a neuromuscular junction of the lobster caused by cannabinoids., 1988, 27, 737-742,","journal-title":"Neuropharmacology"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/jpet.106.116319","volume":"321","author":"S\u00e1nchez-Pastor E.","year":"2007","unstructured":"S\u00e1nchez-Pastor E, Trujillo X, Huerta M, Andrade F. J Pharmacol Exp Ther, Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction., 2007, 321, 439-445,","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"Iannotti F.A.","year":"2016","unstructured":"Iannotti FA, Di Marzo V, Petrosino S. Prog Lipid Res, Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders., 2016, 62, 107-128,","journal-title":"Prog Lipid Res"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","volume":"73","author":"Turcotte C.","year":"2016","unstructured":"Turcotte C, Blanchet MR, Laviolette M, Flamand N. Cell Mol Life Sci, The CB2 receptor and its role as a regulator of inflammation., 2016, 73, 4449-4470,","journal-title":"Cell Mol Life Sci"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/bph.13580","volume":"174","author":"Petrosino S.","year":"2017","unstructured":"Petrosino S, Di Marzo V. Br J Pharmacol, The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations., 2017, 174, 1349-1365,","journal-title":"Br J Pharmacol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.expneurol.2010.03.022","volume":"224","author":"Hansen H.S.","year":"2010","unstructured":"Hansen HS. Exp Neurol, Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain., 2010, 224, 48-55,","journal-title":"Exp Neurol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fncel.2014.00238","volume":"8","author":"Freitag C.M.","year":"2014","unstructured":"Freitag CM, Miller RJ. Front Cell Neurosci, Peroxisome proliferator-activated receptor agonists modulate neuropathic pain: a link to chemokines?, 2014, 8, 238-,","journal-title":"Front Cell Neurosci"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10787-013-0191-7","volume":"22","author":"Skaper S.D.","year":"2014","unstructured":"Skaper SD, Facci L, Fusco M. Inflammopharmacology, Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain., 2014, 22, 79-94,","journal-title":"Inflammopharmacology"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.36076\/ppj\/2016.19.11","volume":"19","author":"Paladini A.","year":"2016","unstructured":"Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Pain Physician, Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis., 2016, 19, 11-24,","journal-title":"Pain Physician"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s12035-015-9253-8","volume":"52","author":"Skaper S.D.","year":"2015","unstructured":"Skaper SD, Facci L, Barbierato M. Mol Neurobiol, N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution., 2015, 52, 1034-1042,","journal-title":"Mol Neurobiol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1073\/pnas.1600251113","volume":"113","author":"Palma E.","year":"2016","unstructured":"Palma E, Reyes-Ruiz JM, Lopergolo D. Proc Natl Acad Sci USA, Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy., 2016, 113, 3060-3065,","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","volume":"21","author":"Di Marzo V.","year":"1998","unstructured":"Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Trends Neurosci, Endocannabinois: endogenous cannabinoid receptor ligands with neuromodulatory action., 1998, 21, 521-528,","journal-title":"Trends Neurosci"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1006\/nbdi.1998.0214","volume":"5","author":"Di Marzo V.","year":"1998","unstructured":"Di Marzo V, Deutsch DG. Neurobiol Dis, Biochemistry of the endogenous ligands of cannabinoid receptors., 1998, 5, 386-404,","journal-title":"Neurobiol Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2005.04.023","volume":"166","author":"Croxford J.L.","year":"2005","unstructured":"Croxford JL, Yamamura T. J Neuroimmunol, Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?, 2005, 166, 3-18,","journal-title":"J Neuroimmunol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1046\/j.1432-1327.2000.01550.x","volume":"267","author":"Salzet M.","year":"2000","unstructured":"Salzet M, Breton C, Bisogno T, Di Marzo V. Eur J Biochem, Comparative biology of the endocannabinoid system. Possible role in the immune response., 2000, 267, 4917-4927,","journal-title":"Eur J Biochem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1155\/2013\/491497","volume":"2013","author":"Kharraz Y.","year":"2013","unstructured":"Kharraz Y, Guerra J, Mann CJ, Serrano AL, Mu\u00f1oz-C\u00e1noves P. Mediators Inflamm, Macrophage plasticity and the role of inflammation in skeletal muscle repair., 2013, 2013, 491-497,","journal-title":"Mediators Inflamm"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"Jaretzki A.","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM. Ann Thorac Surg, Myasthenia gravis: recommendations for clinical research standards. Task Force of the medical scientific advisory board of the myasthenia gravis foundation of America., 2000, 70, 327-334,","journal-title":"Ann Thorac Surg"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1212\/01.WNL.0000163988.28892.79","volume":"64","author":"Bedlack R.S.","year":"2005","unstructured":"Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Neurology, Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity., 2005, 64, 1968-1970,","journal-title":"Neurology"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S1388-2457(01)00546-6","volume":"112","author":"Pavesi G.","year":"2011","unstructured":"Pavesi G, Cattaneo L, Tinchelli S, Mancia D. Clin Neurophysiol, Masseteric repetitive nerve stimulation in the diagnosis of myasthenia gravis., 2011, 112, 1064-1069,","journal-title":"Clin Neurophysiol"},{"key":"ref=22","author":"Kimura J.","year":"1989","unstructured":"Kimura J. ., , 1989, , Electrodiagnosis in diseases of the nerve and muscle: principles and practice 3rd ed. Philadelphia PA: Davis","journal-title":"Electrodiagnosis in diseases of the nerve and muscle: principles and practice 3rd ed Philadelphia PA: Davis"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s13311-016-0420-z","volume":"13","author":"Orefice N.S.","year":"2016","unstructured":"Orefice NS, Alhouayek M, Carotenuto A. Neurotherapeutics, Oral Palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of Interferon-\u03b21a and circulating proinflammatory cytokines in relapsing-remitting Multiple Sclerosis., 2016, 13, 428-438,","journal-title":"Neurotherapeutics"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12975-015-0440-8","volume":"7","author":"Caltagirone C.","year":"2016","unstructured":"Caltagirone C, Cisari C, Schievano C. Transl Stroke Res, Stroke study group Stroke study group. Co-ultramicronized Palmitoylethanolamide\/Luteolin in the treatment of cerebral ischemia: from rodent to man., 2016, 7, 54-69,","journal-title":"Transl Stroke Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2174\/1871527316666170321124949","volume":"16","author":"Brotini S.","year":"2017","unstructured":"Brotini S, Schievano C, Guidi L. CNS Neurol Disord Drug Targets, Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson\u2019s disease., 2017, 16, 705-713,","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbi.2011.02.006","volume":"25","author":"Esposito E.","year":"2011","unstructured":"Esposito E, Paterniti I, Mazzon E. Brain Behav Immun, Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury., 2011, 25, 1099-1112,","journal-title":"Brain Behav Immun"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/npp.2012.25","volume":"37","author":"D\u2019Agostino G.","year":"2012","unstructured":"D\u2019Agostino G, Russo R, Avagliano C, Cristiano C, Meli R, Calignano A. Neuropsychopharmacology, Palmitoylethanolamide protects against the amyloid-\u03b225-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease., 2012, 37, 1784-1792,","journal-title":"Neuropsychopharmacology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.pain.2008.06.003","volume":"139","author":"Costa B.","year":"2008","unstructured":"Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. Pain, The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors., 2008, 139, 541-550,","journal-title":"Pain"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1744-8069-7-3","volume":"7","author":"De Filippis D.","year":"2011","unstructured":"De Filippis D, Luongo L, Cipriano M. Mol Pain, Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats., 2011, 7, 3-,","journal-title":"Mol Pain"},{"key":"ref=30","first-page":"328797","author":"Di Cesare Mannelli L.","year":"2013","unstructured":"Di Cesare Mannelli L, D\u2019Agostino G, Pacini A. Mediators Inflamm, Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism., 2013, 7, 328797-,","journal-title":"Mediators Inflamm"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1871527311312010008","volume":"12","author":"Bettoni I.","year":"2013","unstructured":"Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. CNS Neurol Disord Drug Targets, Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide., 2013, 12, 34-44,","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12974-014-0136-0","volume":"11","author":"Impellizzeri D.","year":"2014","unstructured":"Impellizzeri D, Bruschetta G, Cordaro M. J Neuroinflammation, Micronized\/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain., 2014, 11, 136-,","journal-title":"J Neuroinflammation"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1073\/pnas.92.8.3376","volume":"92","author":"Facci L.","year":"1995","unstructured":"Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Proc Natl Acad Sci USA, Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide., 1995, 92, 3376-3380,","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2174\/1871527313666140806124322","volume":"13","author":"Paterniti I.","year":"2014","unstructured":"Paterniti I, Cordaro M, Campolo M, Siracusa R, Cornelius C, Navarra M, Cuzzocrea S, Esposito E. CNS Neurol Disord Drug Targets, Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer\u2019s disease models: the control of neuroinflammation., 2014, 13, 1530-1541,","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/bph.13084","volume":"173","author":"Petrosino S.","year":"2016","unstructured":"Petrosino S, Schiano Moriello A, Cerrato S. Br J Pharmacol, The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels., 2016, 173, 1154-1162,","journal-title":"Br J Pharmacol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"e0128699","DOI":"10.1371\/journal.pone.0128699","volume":"10","author":"Vacondio F.","year":"2015","unstructured":"Vacondio F, Bassi M, Silva C. PLoS One, Amino acid derivatives as Palmitoylethanolamide prodrugs: synthesis, in vitro metabolism and in vivo plasma profile in rats., 2015, 10, e0128699-,","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/1871527311201070933","volume":"11","author":"Clemente S.","year":"2012","unstructured":"Clemente S. CNS Neurol Disord Drug Targets, Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report., 2012, 11, 933-936,","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1113\/jphysiol.2011.209494","volume":"589","author":"Col\u00f3n-S\u00e1ez J.O.","year":"2011","unstructured":"Col\u00f3n-S\u00e1ez JO, Yakel JL. J Physiol, The \u03b17 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane., 2011, 589, 3163-3174,","journal-title":"J Physiol"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00232-014-9721-5","volume":"247","author":"Trujillo X.","year":"2014","unstructured":"Trujillo X, S\u00e1nchez-Pastor E, Andrade F, Huerta M. J Membr Biol, Presence and colocalization of type-1 cannabinoid receptors with Acetylcholine receptors in the motor end-plate of twitch skeletal muscle fibers in the frog., 2014, 247, 1199-1205,","journal-title":"J Membr Biol"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"Stella N.","year":"2010","unstructured":"Stella N. Glia, Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas., 2010, 58, 1017-1030,","journal-title":"Glia"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2010.02.026","volume":"473","author":"Silveira P.E.","year":"2010","unstructured":"Silveira PE, Silveira NA, Morini Vde C, Kushmerick C, Naves LA. Neurosci Lett, Opposing effect of cannabinoids and vanilloids on evoked quantal release at the frog neuromuscular junction., 2010, 473, 97-101,","journal-title":"Neurosci Lett"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/j.1460-9568.2007.05422.x","volume":"25","author":"Newman Z.","year":"2007","unstructured":"Newman Z, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Eur J Neurosci, Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction., 2007, 25, 1619-1630,","journal-title":"Eur J Neurosci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"Uzawa A.","year":"2014","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S. Clin Exp Immunol, Serum cytokine and chemokine profiles in patients with myasthenia gravis., 2014, 176, 232-237,","journal-title":"Clin Exp Immunol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","volume":"44","author":"Roche J.C.","year":"2011","unstructured":"Roche JC, Capablo JL, Larrad L. Muscle Nerve, Increased serum interleukin-17 levels in patients with myasthenia gravis., 2011, 44, 278-280,","journal-title":"Muscle Nerve"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/08916934.2014.992517","volume":"48","author":"Yilmaz V.","year":"2015","unstructured":"Yilmaz V, Oflazer P, Aysal F. Autoimmunit, B cells produce less IL-10, IL-6 and TNF-\u03b1 in myasthenia gravis., 2015, 48, 201-207,","journal-title":"Autoimmunit"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.410120406","volume":"12","author":"Oh S.","year":"1982","unstructured":"Oh S, Eslami N, Nishihira T, Sarala PK. Ann Neurol, Electrophysiological and clinical correlation in myasthenia gravis., 1982, 12, 348-354,","journal-title":"Ann Neurol"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T07:22:54Z","timestamp":1662880974000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169508\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527318666190131121827","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}